Priya Sriskandarajah

Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study

Christina Guo, Maxime Chénard-Poirier, Desamparados Roda et al. · The Lancet Oncology · 2020 · 74 citations

Medicine, Oncology, Pharmacology +12

Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis

Andreas Reiter, Jason Gotlib, Iván Álvarez‐Twöse et al. · Leukemia · 2022 · 49 citations · Full text

Medicine, Oncology, Pharmacology +13

Retrospective cohort analysis comparing the incidence of deep vein thromboses between peripherally-inserted and long-term skin tunneled venous catheters in hemato-oncology patients

Priya Sriskandarajah, Katharine Webb, David Chisholm et al. · Thrombosis Journal · 2015 · 37 citations · Full text

Medicine, Hematology, Surgery +17

Results from the biomarker-driven basket trial of RO5126766 (CH5127566), a potent RAF/MEK inhibitor, in RAS- or RAF-mutated malignancies including multiple myeloma.

Maxime Chénard-Poirier, Martin Kaiser, Kevin Boyd et al. · Journal of Clinical Oncology · 2017 · 31 citations

Medicine, Oncology, Pharmacology +14

Combined targeting of MEK and the glucocorticoid receptor for the treatment of RAS-mutant multiple myeloma

Priya Sriskandarajah, Alexis de Haven Brandon, Kenneth Macleod et al. · BMC Cancer · 2020 · 15 citations · Full text

Medicine, Oncology, Pharmacology +16